Lowenstein Sandler advised Resilience Lab, a clinician-driven, AI-supported provider of mental health services, in its acquisition of Options MD, a leader in online psychiatric medication management for severe and treatment-resistant depression (TRD). This acquisition enables Resilience Lab to extend its offerings to individuals suffering from severe and treatment-resistant depression (TRD), as well as other moderate to severe mental health conditions.
The deal aligns both organizations' missions to improve access to high-quality mental health care. By integrating Options MD’s specialized expertise in psychiatric care with Resilience Lab’s innovative, therapy-based care model, the combined entity is now positioned to provide comprehensive, advanced treatment options for individuals facing complex mental health challenges.
The Lowenstein deal team included Dotan Barnea, Brendan J. Koeth, Brian A. Silikovitz, James Shehan, Megan Monson, Brianne L. Polito, Judith G. Rubin CIPP/US/E, CIPT, Bianka V. Barraza, Jessica I. Kriegsfeld, Melissa D. Libutti, Bonnie E. Schipper, and Eric Sands.
